Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SHE:300357)

Market Cap	13.25B +14.3%
Revenue (ttm)	1.09B +15.9%
Net Income	425.83M +35.2%
EPS	0.81 +35.2%
Shares Out	523.58M
PE Ratio	31.11
Forward PE	27.20
Dividend	0.25 (0.98%)
Ex-Dividend Date	Jan 20, 2026

Volume	11,073,830
Average Volume	10,940,834
Open	25.51
Previous Close	25.40
Day's Range	25.18 - 25.68
52-Week Range	19.27 - 35.84
Beta	0.46
RSI	42.87
Earnings Date	Apr 24, 2026

About SHE:300357

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of diagnostic and therapeutic products for allergic diseases in China and internationally. The company offers Changdi, a skin prick test product and dust mite drops; Changhao, an Artemisia annua pollen allergen sublingual drop; and Changdian, a dust mite skin prick test diagnostic kit. It is also involved in the research and development of cells and natural medicines. The company was founded in 2002 and is headquartered in Huzhou, China.

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2002
• Employees: 1,808
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300357

Financial Performance

In 2025, SHE:300357's revenue was 1.06 billion, an increase of 14.81% compared to the previous year's 925.39 million. Earnings were 380.94 million, an increase of 19.86%.